
## SÅ,awomir Poletajew

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1275993/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reviews Spontaneous regression of renal cell carcinoma. Wspolczesna Onkologia, 2013, 2, 123-127.	0.7	51
2	Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors. Ortopedia Traumatologia Rehabilitacja, 2011, 13, 537-545.	0.1	40
3	Interobserver variability of <scp>C</scp> lavien– <scp>D</scp> indo scoring in urology. International Journal of Urology, 2014, 21, 1274-1278.	0.5	33
4	The Learning Curve for Transurethral Resection of Bladder Tumour: How Many is Enough to be Independent, Safe and Effective Surgeon?. Journal of Surgical Education, 2020, 77, 978-985.	1.2	25
5	Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients. Urologia Internationalis, 2018, 101, 277-284.	0.6	20
6	Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World Journal of Surgical Oncology, 2018, 16, 6.	0.8	20
7	TGF-β and microRNA Interplay in Genitourinary Cancers. Cells, 2019, 8, 1619.	1.8	19
8	Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review. Urologia Internationalis, 2017, 99, 1-5.	0.6	18
9	What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective. Urologia Internationalis, 2018, 100, 1-12.	0.6	17
10	Urothelial bladder carcinoma in young patients is characterized by a relatively good prognosis. Upsala Journal of Medical Sciences, 2012, 117, 47-51.	0.4	16
11	Renal function and adaptive changes in patients after radical or partial nephrectomy. International Urology and Nephrology, 2012, 44, 745-751.	0.6	16
12	Stage of bladder cancer in Central Europe – Polish perspective. Neoplasma, 2016, 63, 642-647.	0.7	13
13	Influence of Transurethral Resection of Bladder Cancer on Sexual Function, Anxiety, and Depression. Advances in Experimental Medicine and Biology, 2018, 1116, 37-50.	0.8	13
14	The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. Journal of Endourology, 2020, 34, 795-804.	1.1	13
15	MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study. Cancer Biomarkers, 2021, 30, 139-143.	0.8	13
16	The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Urologia Internationalis, 2019, 102, 60-68.	0.6	12
17	Lack of evidence for increased level of circulating urothelial cells in the peripheral blood after transurethral resection of bladder tumors. International Urology and Nephrology, 2012, 44, 761-767.	0.6	11
18	Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour – a prospective multicentre observational study. Archives of Medical Science, 2020, 16, 863-870.	0.4	10

#	Article	IF	CITATIONS
19	Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer. World Journal of Urology, 2020, 38, 3177-3182.	1.2	10
20	The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres – results of CysTiming Poland study. Central European Journal of Urology, 2014, 67, 329-32.	0.2	10
21	Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 651.	1.0	9
22	Scented Candles as an Unrecognized Factor that Increases the Risk of Bladder Cancer; Is There Enough Evidence to Raise a Red Flag?. Cancer Prevention Research, 2019, 12, 645-652.	0.7	8
23	piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers. Biomolecules, 2022, 12, 186.	1.8	8
24	Non-Invasive Biomarkers in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma—A Systematic Review. Cancers, 2022, 14, 1520.	1.7	8
25	Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. BMC Infectious Diseases, 2018, 18, 590.	1.3	7
26	Management of Intradiverticular Bladder Tumours: A Systematic Review. Urologia Internationalis, 2020, 104, 42-47.	0.6	7
27	Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients. Central European Journal of Urology, 2015, 68, 9-14.	0.2	7
28	Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. Journal of Clinical Medicine, 2020, 9, 3195.	1.0	6
29	Diagnostic and treatment delays among patients with primary bladder cancer in Poland: a survey study. Central European Journal of Urology, 2020, 73, 152-159.	0.2	6
30	Surgical treatment for renal masses in the elderly: analysis of oncological, surgical and functional outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 531-540.	0.7	5
31	High-Intensity Focused-Ultrasound Focal Therapy Versus Laparoscopic Radical Prostatectomy: A Comparison of Oncological and Functional Outcomes in Low- and Intermediate-Risk Prostate Cancer Patients. Journal of Personalized Medicine, 2022, 12, 251.	1.1	5
32	The Impact of the Ongoing COVID-19 Epidemic on the Increasing Risk of Adverse Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy. Current Oncology, 2022, 29, 2768-2775.	0.9	5
33	Complications after BCG immunotherapy – neither a mountain nor a molehill. Scandinavian Journal of Urology, 2019, 53, 265-266.	0.6	4
34	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. Journal of Clinical Medicine, 2020, 9, 3306.	1.0	4
35	Predictors and prognostic implications of clinical decisions in patients with primary high-risk non-muscle-invasive bladder cancer – results of a cross country retrospective study. Neoplasma, 2018, 65, 147-152.	0.7	4
36	A prospective, randomized trial comparing the use of KTP (GreenLight) laser versus electroresection-supplemented laser in the treatment of benign prostatic hyperplasia. Central European Journal of Urology, 2016, 69, 391-395.	0.2	4

#	Article	IF	CITATIONS
37	Bimanual palpation for staging of bladder cancer-clinical use and its predictors. Turkish Journal of Urology, 2019, 45, 22-26.	1.3	4
38	Comparison of pathological staging and grading of urothelial bladder carcinoma in post-transurethral resection and post-radical cystectomy specimens. Polish Journal of Pathology, 2014, 4, 305-312.	0.1	3
39	Immunohistochemical differentiation between muscularis mucosae and muscularis propria for improving the staging of bladder cancer in patients undergoing transurethral resection of bladder tumours. Polish Journal of Pathology, 2017, 68, 218-224.	0.1	3
40	Anaesthesia of the posterior urethra and pain reduction during cystoscopy – a randomized controlled trial. Wideochirurgia I Inne Techniki Maloinwazyjne, 2017, 1, 75-80.	0.3	3
41	Expression of E-cadherin, β-catenin, and epithelial membrane antigen does not predict survival in patients with high-risk non-muscle-invasive bladder cancer. Central-European Journal of Immunology, 2018, 43, 421-427.	0.4	3
42	A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette–Guérin immunotherapy. Anti-Cancer Drugs, 2019, 30, 517-522.	0.7	3
43	Bladder perforation during transurethral resection of bladder tumour is not a result of a deficient structure of the bladder wall. World Journal of Surgical Oncology, 2020, 18, 216.	0.8	3
44	Patterns of care in patients with muscle-invasive bladder cancer - a retrospective cohort study. Wspolczesna Onkologia, 2016, 20, 341-3.	0.7	3
45	Multi-Drug Resistant Bacteria as Aetiological Factors of Infections in a Tertiary Multidisciplinary Hospital in Poland. Antibiotics, 2021, 10, 1232.	1.5	3
46	Endoscopic appearance of a tumor can predict the stage of bladder cancer. Central European Journal of Urology, 2017, 70, 27-28.	0.2	3
47	Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52. European Urology, 2017, 71, e29-e30.	0.9	2
48	Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-GuA©rin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-GuA©rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology, 2019, 75, 879-880.	0.9	2
49	Technical developments in transurethral resection of bladder tumours. Wspolczesna Onkologia, 2019, 23, 195-201.	0.7	2
50	Samuel Goldflam (1852-1932) – promoter of modern neurology and his contribution to urology. Central European Journal of Urology, 2012, 65, 113-115.	0.2	2
51	Factors affecting one-year survival after radical cystectomy: a prospective study. Central European Journal of Urology, 2017, 70, 238-244.	0.2	2
52	The incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?. Central European Journal of Urology, 2014, 67, 253-6.	0.2	2
53	Renal carcinoma infiltrating inferior vena cava and combined valvular heart disease - one-stage uro-cardiological procedure: a case report. World Journal of Surgical Oncology, 2010, 8, 63.	0.8	1
54	New predictive nomograms for non-muscle-invasive bladder cancer: it is all about the details. World Journal of Urology, 2020, 38, 805-806.	1.2	1

#	Article	IF	CITATIONS
55	Re: Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non–muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme. European Urology, 2021, 79, 556-557.	0.9	1
56	A stone pushed back to the collecting system – long therapeutic path in centers with limited access to flexible instruments. Central European Journal of Urology, 2018, 71, 186-189.	0.2	1
57	Diagnostic Performance of Preoperative Choline-PET/CT in Patients Undergoing Salvage Lymph Node Dissection for Recurrent Prostate Cancer: A Multicenter Experience. Tomography, 2022, 8, 1090-1096.	0.8	1
58	Availability and Patterns of Intravesical BCG Instillations. Urology Journal, 2017, 14, 5068-5070.	0.3	1
59	Prostate tumour originating from interstitial cells of Cajal: a case presentation and review of the literature. Wspolczesna Onkologia, 2011, 4, 224-228.	0.7	Ο
60	Enhanced power bacillus Calmette-Guérin—possibly too much of a good thing. Translational Andrology and Urology, 2019, 8, S461-S462.	0.6	0
61	A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with nonâ^'muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 606-607.	0.8	0
62	Editorial comment. Urologia Polska, 2013, 65, 20-21.	0.5	0
63	Letter to the Editor. Central European Journal of Urology, 2014, 67, 116.	0.2	0
64	Author's reply. Central European Journal of Urology, 2015, 68, 17.	0.2	0
65	Extent of lymphadenectomy in patients with bladder cancer undergoing radical cystectomy - a multi-institutional analysis. Central European Journal of Urology, 2016, 69, 323-326.	0.2	0
66	A prospective, randomized trial comparing the use of KTP (GreenLight) laser versus electroresection-supplemented laser in the treatment of benign prostatic hyperplasia AUTHOR'S REPLY. Central European Journal of Urology, 2016, 69, 397.	0.2	0
67	The TaHG bladder cancer – the devil is as black as he is painted. Central European Journal of Urology, 2019, 72, 76-77.	0.2	0
68	Urinary Human Kidney Injury Molecule1- (hKIM1-) is not Increased in Patients with Renal Cell Carcinoma. Urology Journal, 2020, 17, 664-666.	0.3	0